Key Takeaways
- • Latticework Capital's Life Science Connect has added Toronto-based biopharma consultant BrevisRefero to its network, according to the primary source headline.
- • BrevisRefero supports drug developers across the lifecycle, from early development through GMP manufacturing and clinical trials.
- • BrevisRefero built the RFP>Navigator outsourcing platform, which the source positions as part of its service offering.
- • The primary source provides limited detail on deal terms, fees, or the nature of the partnership.
Summary
Latticework Capital's Life Science Connect has added BrevisRefero, a biopharmaceutical consultancy based in Toronto, according to the announcement headline. The source describes BrevisRefero as a firm that supports drug developers from early-stage development through good manufacturing practice (GMP) manufacturing and clinical trials.
The source also credits BrevisRefero with building RFP>Navigator, an outsourcing platform. The platform is positioned as a tool connecting drug developers with service providers through the request-for-proposal process, though the primary source offers limited detail on its functionality or adoption.
The primary source does not disclose financial terms, the scope of the arrangement, or the stated rationale for the addition. Readers seeking further detail on how the relationship will operate or what it means for Life Science Connect's network should refer to the full publication.
The source also credits BrevisRefero with building RFP>Navigator, an outsourcing platform. The platform is positioned as a tool connecting drug developers with service providers through the request-for-proposal process, though the primary source offers limited detail on its functionality or adoption.
The primary source does not disclose financial terms, the scope of the arrangement, or the stated rationale for the addition. Readers seeking further detail on how the relationship will operate or what it means for Life Science Connect's network should refer to the full publication.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.